期刊
FUTURE ONCOLOGY
卷 11, 期 3, 页码 449-465出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.261
关键词
adverse event management; Child-Pugh B; dose modification; elderly; hepatocellular carcinoma; mRECIST; postprogression treatment; real-world data; response assessment; sorafenib
类别
资金
- Bayer HealthCare Pharmaceuticals
- BMS
- Bracco
- Syrtex
- Bayer
- Novartis
- Roche
- Merck Serono
- Gilead Science
- Tibotec
- Vertex
- Merck
- Janssen
- Sanofi
- Bayer SpA
Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symptomatic progression should also be considered. If second-line therapies or trials are unavailable, continuing sorafenib beyond radiologic progression may provide a clinical benefit. Our recommendations enable the maximization of treatment duration, and hence clinical benefit, for patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据